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Patients with Neuroﬁbromatosis type 1 (NF1) have an increased risk of developing neoplasms. The most common brain tumors,
found in 15%–20% of NF1 patients, are hypothalamic-optic gliomas, followed by brainstem and cerebellar pilocytic astrocytomas.
These tumors generally have a benign nature. NF1 patients are predisposed to a 5-fold increased incidence of high-grade
astrocytomas, which are usually located in supratentorial regions of the brain. We present an NF1 patient who developed a high-
grade astrocytoma in the posterior fossa and discuss possible pathophysiological mechanisms.
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1.Introduction
Neuroﬁbromatosis type 1 is the most common neurocuta-
neousdiseasewithaprevalenceofapproximately1in2600to
1 in 3000 individuals [1]. The majority of Neuroﬁbromatosis
type1(NF1)patientsareonlymildlyaﬀected,buttheclinical
course is highly variable, though generally progressive [2].
The cardinal feature of NF1 is the development of multiple
neuroﬁbromas, with a 10% lifetime risk of progressing
to malignant peripheral nerve sheath tumors (MPNSTs)
[3]. Other characteristics include (in order of appearance)
caf´ e au lait spots, skin fold freckles, Lisch nodules, and
skeletal anomalies [4]. In addition, NF1 patients have an
increased risk of developing neoplasms, such as leukemia,
pheochromocytomas, and brain tumors [5, 6]. The most
common of these are hypothalamic-optic gliomas, followed
by brainstem and cerebellar pilocytic astrocytomas (see for a
review [7]).
Theastrocytomasobservedin15%–20%ofthesepatients
generally have a benign nature [8]. NF1 patients however
have a 5-fold increased incidence of high-grade astrocytoma
(WHO grade IV), also known as glioblastoma multiforme
(GBM) [9].
These tumors are usually located in supratentorial
regions of the brain.
We present a 28-year-old female NF1 patient who
developed a GBM in the posterior cranial fossa and discuss
the possible pathophysiological mechanisms.
2.CaseReport
2.1. History and Presentation. The patient, a 28-year-old
woman with NF1 was regularly seen for follow-up of a
cerebellar lesion, suspected to be a hamartoma. This lesion
was accidentally discovered during a radiological exam
performed for a facial neuroﬁbroma, when she was 21 years
old. Successive MRI-scans of the brain were performed.
At the age of 28, she was referred to our hospital because
of complaints of progressive balance disturbance, ataxia of
therightarmandleg,diplopia,andasenseofpulsationatthe
back of her head. She mentioned that a “bump” at the back
of her head had increased in size over the preceding months.
Neurological examination revealed nystagmus of her
right eye, diplopia, loss of sensibility of the face, and ataxia
of the right arm and leg. Romberg’s test was positive. An
occipital/cerebellar solid mass of 4 by 5cm was palpable.2 Case Reports in Medicine
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Figure 1: T1-weighted axial MRI-scan of the brain. T1-weighted axial MRI showed a (sub)occipital right-sided bone defect and a lesion in
the right cerebellar hemisphere (a) that enhanced after i.v. Gadolinium administration (b).
AnMRI-scanofthebrain(Figures1(a)and1(b))showed
a (sub)occipital right-sided bone defect,contiguous to a sub-
cutaneous neuroﬁbroma, and a lesion in the right cerebellar
hemisphere that enhanced after Gadolinium administration
(Figure 1(b)). In the left cerebellar hemisphere and the left
superior colliculus other lesions were found, that both also
enhanced upon Gadolinium administration.
2.2. Treatment, Histological Evaluation and Postoperative
Course. Neurosurgical resection of the lesion was subse-
quently performed. Histological analysis revealed two dis-
tinct lesions: a mitotically active pleomorphic astrocytoma
with pathologic vascular proliferation that was classiﬁed as
glioblastoma multiforme (astrocytoma, grade 4) (Figures
2(a), 2(c), 2(e),a n d2(f))a n dad i ﬀuse neuroﬁbroma
(Figures 2(b) and 2(d)). The former showed leptomeningeal
involvement, and the latter was restricted to the subcutis.
On immunohistochemistry, the ﬁrst lesion was positive
for GFAP (Figure 2(c)), the second negative (data not
shown), but positive for S100 (Figure 2(d)). Approximately
10%–15% of the nuclei of the ﬁrst lesion were positive for
the proliferation marker Ki67 (MiB1) (Figure 2(e))a n d1 %
of the nuclei of the neuroﬁbroma (data not shown).
Approximately 30% of the cells in the ﬁrst lesion showed
immunopositivity for p53 (Figure 2(f)).
Upon recovery from surgery, the patient underwent
both radiotherapy and chemotherapy. Six months later, MR-
imaging showed progression of the tumor. After another six
months metastases were present in the right frontal lobe and
spine. The patient died shortly thereafter.
3. Discussion
NF1 patients have an increased risk of developing central
nervous system malignancies [5]. Besides optic pathway
gliomas that arise in 15% of NF1 patients before the age
of 7 [10], these patients are at increased risk for developing
other astrocytomas. Even though the mean age at diagnosis
has been reported to be 4.5 years, the risk of developing
astrocytomas persists into adulthood [11].
This risk is accompanied by a 5-fold increased incidence
of high-grade astrocytoma [9]. Several predisposing factors
have been suggested: optic pathway glioma, hyperintense
lesionsonaT2-weighedMRI,andhereditaryfactors[12,13].
However, it is still impossible to predict the development and
localization of brain tumors in NF1-patients.
Mutations at the NF1 gene, which is a tumor suppressor
gene located on chromosome 17q11.2, can partly explain the
clinical susceptibility for malignancies. The NF1 gene prod-
uctneuroﬁbrominfunctionsinpartasanegativeregulatorof
thep21Rasproto-oncogenebyacceleratingtheconversionof
active guanosine triphosphate- (GTP-)bound Ras to its inac-
tive guanosine diphosphate- (GDP-)bound form. Active Ras,
as a result of reduced or absent neuroﬁbromin expression,
leadstoincreasedcellgrowthandfacilitatestumorformation
[14]. This growth regulatory function of neuroﬁbromin
cannot fully explain the discrepancy between some tumors
in NF1 patients that stay quiescent for many years and others
thatrapidlychangetowardmalignancy.Ithasbeensuggested
that mutations in other genes may cooperate with NF1
mutations in the cancerogenesis observed in these patients.
For most tumors found in NF1 patients, the genetic events
contributing to their development remain to be elucidated.
Molecular analysis of GBMs arising in NF1 patients showed
the presence of genetic alterations such as p16INK4A/ARF
deletions and p53 mutations, which are often also present
in sporadic GBMs [8]. These alterations are believed to
cooperate with NF1 loss in the development of malignant
astrocytomas.
Several groups have conﬁrmed the cooperation of muta-
tions in NF1 and p53 in the development of astrocytomas
in transgenic mice [15, 16]. Zhu et al. reported that in
their mouse model with simultaneous loss of p53 andCase Reports in Medicine 3
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Figure 2: Histopathological and immunohistochemical ﬁndings. Histology of the ﬁrst lesion showed a cellular astrocytic neoplasm (H&E)
(a). The second lesion impressed as a neuroﬁbroma (H&E) (b). The ﬁrst lesion was GFAP positive (c), whereas the second was not (data not
shown). This lesion was however positive for S100 (d). ∼10%–15% of the nuclei of the ﬁrst lesion were immunohistochemically stained for
Ki-67 (MiB1) (e). In this lesion, approximately 30% of the cells showed immonupositivity for p53 (f).
NF1, most tumors arose in the vicinity of the subventric-
ular zone (SVZ), where the majority of neural precursor
cells reside [16]. This might indicate two things: ﬁrst,
cells in this region of the brain are more susceptible to
p53/NF1-mediated tumor formation. Interestingly, it has
been suggested that even though cells in diﬀerent regions
of the brain might seem morphologically identical, they
are in fact unique. For example, neural precursor cells
isolated from diﬀerent regions of the human embryonic
brain exhibit distinct growth properties [17]. Moreover,
neocortical and cerebellar astrocytes display diﬀerent bio-
logical and electrophysiological properties [18–23]. Finally
ependymomas and pilocytic astrocytomas arising in supra-
tentorial versus infratentorial regions of the brain display
considerably diﬀerent gene expression proﬁles [24, 25].
Second, the micromilieu of the SVZ is more advanta-
geous to the growth of brain tumor precursor cells. Most
high-grade astrocytomas in NF1 patients are found in
supratentorial regions of the brain. Here, we present an
NF-1 patient who developed a GBM in the posterior
fossa.
As in the NF1/p53 transgenic mouse model, the GBM
tumor in this NF1 patient also showed loss of p53. The
cerebellarlocationofthistumorseemstobeassociatedwitha
pre-existing lesion, which may have created an environment
conducive to mutagenesis and/or supportive for tumor
initiating cells.
The characteristics of this single case suggest that brain-
lesions in NF1-patients should be closely monitored for
potential developmentofhigh-grade astrocytomas.Asimilar
suggestion was made earlier by Carella et al. [26]. However,
larger studies will be necessary to establish a ﬁrm correlation
between lesions and development of high-grade astrocy-
tomas in NF1 patients.4 Case Reports in Medicine
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